Global Direct Endoscopic Necrosectomy Market

Direct Endoscopic Necrosectomy Comprehensive Study by Type (Abdominal Scan, X-ray, Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Abdominal Biopsy, Urine test), Application (Hospitals, Clinics, Rehabilitation Centers, Others), Treatment (Pancreatic Necrosis, Pseudocysts) Players and Region - Global Market Outlook to 2028

Direct Endoscopic Necrosectomy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Direct endoscopic necrosectomy is an invasive endoscopic technique for the treatment of infected walled-off pancreatic necrosis and infected pseudocysts with solid debris. The lack of dedicated devices for this purpose largely affects the possibility of safely performing DEN which increases the risk of complications. We present the case of a 63 years-old man who underwent an endoscopic ultrasound (EUS)-guided drainage of a WOPN, and who was readmitted one month after stent removal with clinical, endoscopic, and radiological signs of infected necrosis involving the splenic artery.

Highlights from Direct Endoscopic Necrosectomy Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The key Players profiled in the report are Interscope (United States), Olympus Corporation (Japan), Ethicon Endo-surgery (United States), FUJIFILM Holdings Corporation (Japan), Stryker Corporation (United States), Boston Scientific Corporation (United States), Karl Storz GmbH (Germany) and Smith & Nephew Inc (United Kingdom). Additionally, other players that are part of this comprehensive study are Richard Wolf GmbH (Germany), Medtronic Plc (Ireland), Machida Endoscope Co (Japan) and Others.

Geographic Breakdown and Segment Analysis
The Global Direct Endoscopic Necrosectomy market presents a comprehensive analysis of the Direct Endoscopic Necrosectomy market by product type (Abdominal Scan, X-ray, Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Abdominal Biopsy and Urine test), by end-user/application (Hospitals, Clinics, Rehabilitation Centers and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Direct Endoscopic Necrosectomy industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Direct Endoscopic Necrosectomy market

Analyst at AMA have segmented the market study of Global Direct Endoscopic Necrosectomy market by Type, Application and Region.

Influencing Trend:
Increasing Investment in R&D Activities to Develop Innovative Systems and Solutions for Direct Endoscopic Necrosectomy

Market Growth Drivers:
Growing Use of Direct Endoscopic Necrosectomy in Pancreatic Pseudocyst Treatment Due to Lower Morbidity

Restraints:
Slow Adoption of Direct Endoscopic Necrosectomy in Some Developing and Under Developed Countries Due to Less Awareness

Opportunities:
Increasing Initiatives of Multispecialty Hospitals to Adopt Cutting-edge Technologies and Devices for Easy and Less Painful Treatment

Market Developments Activities:
In August 2022, Direct endoscopic necrosectomy (DEN) has become the standard first-line treatment for symptomatic pancreatic walled-off necrosis. The use of the Axios lumen-apposing metal stent (LAMS) system is increasingly popular for this procedure because of its bi-flanged design, large diameters, and lower risk of migration or occlusion. However, up to 10% of patients don’t respond and ultimately require surgery.
In 2020, Interscope, Inc.'s EndoRotor System for direct endoscopic necrosectomy received clearance from the FDA de novo for application in the United States market. The system allows physicians to simultaneously resect and aspirate necrotic material from the wall-off pancreatic collection through a lumen apposing metal stent or cystogastrostomy.



The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of the new system, which is likely to encourage the growth of the global market throughout the forecast period.

Key Target Audience
Key Target Audience, New Entrants/Investors, Analysts and Strategic Business Planners, Direct Endoscopic Necrosectomy Solutions Providers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations, End-users and Others

Report Objectives / Segmentation Covered

By Type
  • Abdominal Scan
  • X-ray
  • Single Photon Emission Computed Tomography (SPECT)
  • Positron Emission Tomography (PET)
  • Abdominal Biopsy
  • Urine test
By Application
  • Hospitals
  • Clinics
  • Rehabilitation Centers
  • Others
By Treatment
  • Pancreatic Necrosis
  • Pseudocysts

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Use of Direct Endoscopic Necrosectomy in Pancreatic Pseudocyst Treatment Due to Lower Morbidity
    • 3.3. Market Trends
      • 3.3.1. Increasing Investment in R&D Activities to Develop Innovative Systems and Solutions for Direct Endoscopic Necrosectomy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Direct Endoscopic Necrosectomy, by Type, Application, Treatment and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Direct Endoscopic Necrosectomy (Value)
      • 5.2.1. Global Direct Endoscopic Necrosectomy by: Type (Value)
        • 5.2.1.1. Abdominal Scan
        • 5.2.1.2. X-ray
        • 5.2.1.3. Single Photon Emission Computed Tomography (SPECT)
        • 5.2.1.4. Positron Emission Tomography (PET)
        • 5.2.1.5. Abdominal Biopsy
        • 5.2.1.6. Urine test
      • 5.2.2. Global Direct Endoscopic Necrosectomy by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Rehabilitation Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Direct Endoscopic Necrosectomy by: Treatment (Value)
        • 5.2.3.1. Pancreatic Necrosis
        • 5.2.3.2. Pseudocysts
      • 5.2.4. Global Direct Endoscopic Necrosectomy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Direct Endoscopic Necrosectomy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Interscope (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Olympus Corporation (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ethicon Endo-surgery (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. FUJIFILM Holdings Corporation (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Stryker Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boston Scientific Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Karl Storz GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Smith & Nephew Inc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Direct Endoscopic Necrosectomy Sale, by Type, Application, Treatment and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Direct Endoscopic Necrosectomy (Value)
      • 7.2.1. Global Direct Endoscopic Necrosectomy by: Type (Value)
        • 7.2.1.1. Abdominal Scan
        • 7.2.1.2. X-ray
        • 7.2.1.3. Single Photon Emission Computed Tomography (SPECT)
        • 7.2.1.4. Positron Emission Tomography (PET)
        • 7.2.1.5. Abdominal Biopsy
        • 7.2.1.6. Urine test
      • 7.2.2. Global Direct Endoscopic Necrosectomy by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Rehabilitation Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Direct Endoscopic Necrosectomy by: Treatment (Value)
        • 7.2.3.1. Pancreatic Necrosis
        • 7.2.3.2. Pseudocysts
      • 7.2.4. Global Direct Endoscopic Necrosectomy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Direct Endoscopic Necrosectomy: by Type(USD Million)
  • Table 2. Direct Endoscopic Necrosectomy Abdominal Scan , by Region USD Million (2017-2022)
  • Table 3. Direct Endoscopic Necrosectomy X-ray , by Region USD Million (2017-2022)
  • Table 4. Direct Endoscopic Necrosectomy Single Photon Emission Computed Tomography (SPECT) , by Region USD Million (2017-2022)
  • Table 5. Direct Endoscopic Necrosectomy Positron Emission Tomography (PET) , by Region USD Million (2017-2022)
  • Table 6. Direct Endoscopic Necrosectomy Abdominal Biopsy , by Region USD Million (2017-2022)
  • Table 7. Direct Endoscopic Necrosectomy Urine test , by Region USD Million (2017-2022)
  • Table 8. Direct Endoscopic Necrosectomy: by Application(USD Million)
  • Table 9. Direct Endoscopic Necrosectomy Hospitals , by Region USD Million (2017-2022)
  • Table 10. Direct Endoscopic Necrosectomy Clinics , by Region USD Million (2017-2022)
  • Table 11. Direct Endoscopic Necrosectomy Rehabilitation Centers , by Region USD Million (2017-2022)
  • Table 12. Direct Endoscopic Necrosectomy Others , by Region USD Million (2017-2022)
  • Table 13. Direct Endoscopic Necrosectomy: by Treatment(USD Million)
  • Table 14. Direct Endoscopic Necrosectomy Pancreatic Necrosis , by Region USD Million (2017-2022)
  • Table 15. Direct Endoscopic Necrosectomy Pseudocysts , by Region USD Million (2017-2022)
  • Table 16. South America Direct Endoscopic Necrosectomy, by Country USD Million (2017-2022)
  • Table 17. South America Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 18. South America Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 19. South America Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 20. Brazil Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 21. Brazil Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 22. Brazil Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 23. Argentina Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 24. Argentina Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 25. Argentina Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 26. Rest of South America Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 29. Asia Pacific Direct Endoscopic Necrosectomy, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 33. China Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 34. China Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 35. China Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 36. Japan Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 37. Japan Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 38. Japan Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 39. India Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 40. India Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 41. India Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 42. South Korea Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 43. South Korea Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 44. South Korea Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 45. Taiwan Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 46. Taiwan Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 47. Taiwan Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 48. Australia Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 49. Australia Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 50. Australia Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 54. Europe Direct Endoscopic Necrosectomy, by Country USD Million (2017-2022)
  • Table 55. Europe Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 56. Europe Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 57. Europe Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 58. Germany Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 59. Germany Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 60. Germany Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 61. France Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 62. France Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 63. France Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 64. Italy Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 65. Italy Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 66. Italy Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 67. United Kingdom Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 70. Netherlands Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 71. Netherlands Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 72. Netherlands Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 73. Rest of Europe Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 76. MEA Direct Endoscopic Necrosectomy, by Country USD Million (2017-2022)
  • Table 77. MEA Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 78. MEA Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 79. MEA Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 80. Middle East Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 81. Middle East Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 82. Middle East Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 83. Africa Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 84. Africa Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 85. Africa Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 86. North America Direct Endoscopic Necrosectomy, by Country USD Million (2017-2022)
  • Table 87. North America Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 88. North America Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 89. North America Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 90. United States Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 91. United States Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 92. United States Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 93. Canada Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 94. Canada Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 95. Canada Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 96. Mexico Direct Endoscopic Necrosectomy, by Type USD Million (2017-2022)
  • Table 97. Mexico Direct Endoscopic Necrosectomy, by Application USD Million (2017-2022)
  • Table 98. Mexico Direct Endoscopic Necrosectomy, by Treatment USD Million (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Direct Endoscopic Necrosectomy: by Type(USD Million)
  • Table 108. Direct Endoscopic Necrosectomy Abdominal Scan , by Region USD Million (2023-2028)
  • Table 109. Direct Endoscopic Necrosectomy X-ray , by Region USD Million (2023-2028)
  • Table 110. Direct Endoscopic Necrosectomy Single Photon Emission Computed Tomography (SPECT) , by Region USD Million (2023-2028)
  • Table 111. Direct Endoscopic Necrosectomy Positron Emission Tomography (PET) , by Region USD Million (2023-2028)
  • Table 112. Direct Endoscopic Necrosectomy Abdominal Biopsy , by Region USD Million (2023-2028)
  • Table 113. Direct Endoscopic Necrosectomy Urine test , by Region USD Million (2023-2028)
  • Table 114. Direct Endoscopic Necrosectomy: by Application(USD Million)
  • Table 115. Direct Endoscopic Necrosectomy Hospitals , by Region USD Million (2023-2028)
  • Table 116. Direct Endoscopic Necrosectomy Clinics , by Region USD Million (2023-2028)
  • Table 117. Direct Endoscopic Necrosectomy Rehabilitation Centers , by Region USD Million (2023-2028)
  • Table 118. Direct Endoscopic Necrosectomy Others , by Region USD Million (2023-2028)
  • Table 119. Direct Endoscopic Necrosectomy: by Treatment(USD Million)
  • Table 120. Direct Endoscopic Necrosectomy Pancreatic Necrosis , by Region USD Million (2023-2028)
  • Table 121. Direct Endoscopic Necrosectomy Pseudocysts , by Region USD Million (2023-2028)
  • Table 122. South America Direct Endoscopic Necrosectomy, by Country USD Million (2023-2028)
  • Table 123. South America Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 124. South America Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 125. South America Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 126. Brazil Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 127. Brazil Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 128. Brazil Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 129. Argentina Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 130. Argentina Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 131. Argentina Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 132. Rest of South America Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 133. Rest of South America Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 134. Rest of South America Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 135. Asia Pacific Direct Endoscopic Necrosectomy, by Country USD Million (2023-2028)
  • Table 136. Asia Pacific Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 137. Asia Pacific Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 138. Asia Pacific Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 139. China Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 140. China Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 141. China Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 142. Japan Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 143. Japan Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 144. Japan Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 145. India Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 146. India Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 147. India Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 148. South Korea Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 149. South Korea Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 150. South Korea Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 151. Taiwan Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 152. Taiwan Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 153. Taiwan Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 154. Australia Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 155. Australia Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 156. Australia Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 157. Rest of Asia-Pacific Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 158. Rest of Asia-Pacific Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 160. Europe Direct Endoscopic Necrosectomy, by Country USD Million (2023-2028)
  • Table 161. Europe Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 162. Europe Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 163. Europe Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 164. Germany Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 165. Germany Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 166. Germany Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 167. France Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 168. France Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 169. France Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 170. Italy Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 171. Italy Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 172. Italy Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 173. United Kingdom Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 174. United Kingdom Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 175. United Kingdom Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 176. Netherlands Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 177. Netherlands Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 178. Netherlands Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 179. Rest of Europe Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 180. Rest of Europe Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 181. Rest of Europe Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 182. MEA Direct Endoscopic Necrosectomy, by Country USD Million (2023-2028)
  • Table 183. MEA Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 184. MEA Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 185. MEA Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 186. Middle East Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 187. Middle East Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 188. Middle East Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 189. Africa Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 190. Africa Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 191. Africa Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 192. North America Direct Endoscopic Necrosectomy, by Country USD Million (2023-2028)
  • Table 193. North America Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 194. North America Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 195. North America Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 196. United States Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 197. United States Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 198. United States Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 199. Canada Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 200. Canada Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 201. Canada Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 202. Mexico Direct Endoscopic Necrosectomy, by Type USD Million (2023-2028)
  • Table 203. Mexico Direct Endoscopic Necrosectomy, by Application USD Million (2023-2028)
  • Table 204. Mexico Direct Endoscopic Necrosectomy, by Treatment USD Million (2023-2028)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Direct Endoscopic Necrosectomy: by Type USD Million (2017-2022)
  • Figure 5. Global Direct Endoscopic Necrosectomy: by Application USD Million (2017-2022)
  • Figure 6. Global Direct Endoscopic Necrosectomy: by Treatment USD Million (2017-2022)
  • Figure 7. South America Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 8. Asia Pacific Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 9. Europe Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 10. MEA Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 11. North America Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 12. Global Direct Endoscopic Necrosectomy share by Players 2022 (%)
  • Figure 13. Global Direct Endoscopic Necrosectomy share by Players (Top 3) 2022(%)
  • Figure 14. Global Direct Endoscopic Necrosectomy share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Interscope (United States) Revenue, Net Income and Gross profit
  • Figure 17. Interscope (United States) Revenue: by Geography 2022
  • Figure 18. Olympus Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 19. Olympus Corporation (Japan) Revenue: by Geography 2022
  • Figure 20. Ethicon Endo-surgery (United States) Revenue, Net Income and Gross profit
  • Figure 21. Ethicon Endo-surgery (United States) Revenue: by Geography 2022
  • Figure 22. FUJIFILM Holdings Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 23. FUJIFILM Holdings Corporation (Japan) Revenue: by Geography 2022
  • Figure 24. Stryker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 25. Stryker Corporation (United States) Revenue: by Geography 2022
  • Figure 26. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Boston Scientific Corporation (United States) Revenue: by Geography 2022
  • Figure 28. Karl Storz GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Karl Storz GmbH (Germany) Revenue: by Geography 2022
  • Figure 30. Smith & Nephew Inc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Smith & Nephew Inc (United Kingdom) Revenue: by Geography 2022
  • Figure 32. Global Direct Endoscopic Necrosectomy: by Type USD Million (2023-2028)
  • Figure 33. Global Direct Endoscopic Necrosectomy: by Application USD Million (2023-2028)
  • Figure 34. Global Direct Endoscopic Necrosectomy: by Treatment USD Million (2023-2028)
  • Figure 35. South America Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 36. Asia Pacific Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 37. Europe Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 38. MEA Direct Endoscopic Necrosectomy Share (%), by Country
  • Figure 39. North America Direct Endoscopic Necrosectomy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Interscope (United States)
  • Olympus Corporation (Japan)
  • Ethicon Endo-surgery (United States)
  • FUJIFILM Holdings Corporation (Japan)
  • Stryker Corporation (United States)
  • Boston Scientific Corporation (United States)
  • Karl Storz GmbH (Germany)
  • Smith & Nephew Inc (United Kingdom)
Additional players considered in the study are as follows:
Richard Wolf GmbH (Germany) , Medtronic Plc (Ireland) , Machida Endoscope Co (Japan) , Others
Select User Access Type

Key Highlights of Report


Dec 2023 144 Pages 97 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Direct Endoscopic Necrosectomy Market Quantitative research analysis
Global Direct Endoscopic Necrosectomy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2028
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.

Know More About Global Direct Endoscopic Necrosectomy Market Report?

Have a Query? Click Here

Other Related Reports

Lyme Disease Treatment Comprehensive Study by Type (Doxycycline, Amoxicillin, Cefuroxime axetil, Ceftriaxone, Others), Application (Humans, Animals), Disease (Early Lyme disease (absence of erythema ...
$ 3750
Acne Scar Treatment Comprehensive Study by Type (Laser Treatments, Minor Skin Surgeries, Chemical Peels, Fillers, Others), Application (Minimize Small Scars, Minor Skin Surface Irregularities, Surgic...
$ 3450
Genital Warts Treatment Comprehensive Study by Drug Type (Podophyllotoxin, Imiquimod, Sinecatechins, Podophyllin, 5-FU), Mechanism of Action (Immunomodulators, Immunomodulators; Virus Internalization...
$ 3650
Pancreatic Amylase Reagent Comprehensive Study by Function (Digestion Of Carbohydrate, Producing Glucose), Causes And Risk Factor (Autoimmune diseases, Drinking lots of alcohol, Infections, Gallstone...
$ 3750
Agoraphobia Treatment Comprehensive Study by Application (Hospitals, Specialty Clinic Center, Others), Therapy (Psychotherapy, Cognitive Behavioral Therapy (CBT), Exposure Therapy, Other), Medication...
$ 3650
Trauma Fixation - Comprehensive Study by Type (Internal Fixation, External Fixation), Application (Shoulder Fracture, Wrist Fracture, Femur Fracture, Ankle Fracture, Deformity Fracture, Others), End ...
$ 3650